Physician profile
David Widman
NPI 1821168816
$7,497.77
in general payments reported to CMS, 2019-2025
32 companies · $653 in 2025
The $653 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,934 · 2020: $417 · 2021: $41.18 · 2022: $426 · 2023: $1,290 · 2024: $1,736 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.94 |
| Education | $464.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,779.82 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,214.24 | 2019-2025 | |
| Abbvie INC. | $768.50 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $714.22 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Janssen Scientific Affairs, LLC | $558.30 | 2019-2023 | Tremfya |
| Genentech USA, INC. | $453.90 | 2019 | |
| Ucb, INC. | $445.86 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $321.41 | 2019-2024 | Benlysta |
| Pfizer INC. | $134.25 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $118.95 | 2024-2025 | Idacio |
| Genzyme Corporation | $105.67 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $88.50 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $87.35 | 2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $73.01 | 2019-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $66.75 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $63.72 | 2019 | |
| Bioventus LLC | $62.36 | 2020-2025 | Durolane |
| Lilly USA, LLC | $57.68 | 2019-2024 | Taltz |
| Hikma Pharmaceuticals USA | $56.23 | 2019-2020 | |
| Celgene Corporation | $43.98 | 2019 | |
| Merck Sharp & Dohme LLC | $39.14 | 2019 | |
| Radius Health, INC. | $35.30 | 2024 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $34.56 | 2023-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.55 | 2020-2024 | Ofev |
| Alexion Pharmaceuticals, INC. | $29.29 | 2024 | Strensiq |
| Organon LLC | $28.27 | 2021-2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.07 | 2023 | Arcalyst |
| Sobi, INC | $14.98 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.92 | 2019 | |
| Pacira Therapeutics, INC. | $14.40 | 2020 | |
| Mylan Institutional INC. | $14.33 | 2023 | Hulio |
| Sanofi Pasteur INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Widman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.